Registro de fonte primária
Nível de decisãoResultados topline
Adicet Bio: dados topline de prula-cel para LES previstos para setembro de 2026
Last patient visit completed for the planned Phase 1 analysis of prula-cel in SLE with or without LN. Topline data from 22 patients (13 with ≥12 months follow-up) are now scheduled for release in September 2026. The company also notes FDA alignment on outpatient dosing and ongoing registrational trial design discussions.
Fatos principais
- Arquivado
- 1 de set. de 2026, 11:02
- Evento
- Resultados topline
- Direção
- Neutro
- Empresa
ACETAdicet Bio- Fonte
- SEC 8-K
- Confiança
- Com fonte
- pacientes 12 meses
- 13
- pacientes analisados
- 22
Trecho da fonte
EX-99.1 2 acet-ex99_1.htm EX-99.1 EX-99.1 Adicet Bio Announces Completion of Last Patient Visit for Planned Analysis of prula-cel (formerly ADI-001) Study in Patients with Systemic Lupus Erythematosus With or Without Lupus Nephritis and Provides Corporate Update Prula-cel topline results from planned analysis expected September 2026 FDA clearance of IND for ADI-212 in mCRPC; Phase 1 clinical study expected to initiate in 4Q 2026 Unveiling next-generation in vivo CAR-T platform and pipeline targeting hematological malignancies and solid tumors; first candidate expected to enter clinical development in 2H 2027 REDWOOD CITY, Calif. – September 1, 2026 – Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta CAR T cell an